AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04586855 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Ultrasound
Description: To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
Study NCT04586855 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transnasal Fiberoptic Laryngoscopy
Description: To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
Study NCT06444282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emergency Care Action Plan
Description: An Emergency Care Action Plan (ECAP) is a brief, pre-populated summary of suggested emergency management for children with medical complexity, embedded in a patient's electronic health record for access by providers in an emergency. Patients/families will have digital access to the ECAP and be given a paper copy. The patient's care team and caregiver(s) (parent/legal guardian) will collaborate to create an individualized ECAP containing the following content: caregiver contact information, patient summary, anticipated emergency presentations with suggested management, problem list (emergency relevant only), medication list, technology dependence, baseline important physical exam findings, baseline vital signs, allergies, advance directive information, contact information for established care providers, and other important information.
Study NCT05387291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention group will undergo an education program related to the circumcision process for the child's relatives/guardians.
Study NCT05387291 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: The control group will receive the usual intervention of the center.
Study NCT05846724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Lenvatinib
Description: single-arm study of pembrolizumab plus lenvatinib
Study NCT05439759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 3: Training spatial attention
Description: The investigators will implement a task structure that requires participants to alternate between holding and switching attention and making targeted eye movements. The basic task is to press a key whenever a red-circle appears in a series of other colored-circles, with a target presented every 2 to 4s. Participants must maintain vigilance for relatively long periods, detect objects in the near periphery, switch attention based upon exogenous and endogenous cues, and make eye- movements to move areas of spared vision to those locations. These are aspects of attention and eye movements not incorporated in Conditions 1 and 2.
Study NCT05439759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 4: Combination training
Description: Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision,Condition 4 combines the elements of Conditions 1-3.
Study NCT05512715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radioactive iodine
Description: radioactive iodine 15mci
Study NCT05880628 — intervention group
Intervention type: OTHER
Intervention: datas of medical record.
Description: Analysis datas of medical record:~* Feasibility of the technique~* Safety of the technique~* Efficacity (sclerose of the lesion)
Study NCT05327023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: donor lymphocyte infusion
Description: The DLI will be given on Day +7 (Day +21 for dose level -1). If a recipient participant is deemed too critically ill/unstable to receive DLI on the protocol specified day, the DLI will be delayed up to 4 days at the discretion of the PI and given within this time frame once the recipient participant s clinical status has stabilized or improved. If the DLI cannot be given during this time frame, the recipient participant will be taken off study and not considered evaluable for DLT, outcomes, or adverse events since the experimental intervention will not have been given.
Study NCT05327023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: HLA-matched: 50 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight. HLA haploidentical: 25 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight.
Study NCT05327023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: AUC targeted dose based on busulfan test dose, with a default dose of 130 mg/m2/day, given as IV infusion over 3 hours each day for 4 days Transplant days -6 through day -3
Study NCT05327023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.
Study NCT05327023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2 IV infusion over 30-60 minutes once daily for 4 days Transplant days -6 through -3
Study NCT05327023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, maximum initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +70 with no taper. Doses should be modified as appropriate for drug interactions.
Study NCT05069428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramelteon 8mg
Description: administered crushed, orally at 20:30
Study NCT05069428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon 8mg
Description: administered crushed, orally at 20:30
Study NCT05078801 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic drainage
Description: ERCP and/or EUS-guided biliary drainage
Study NCT05078801 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous transhepatic biliary drainage
Description: US or CT-guided percutaneous drainage
Study NCT05324709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Based Stress Management Program
Description: Yoga-based stress management program is applied to the intervention group.
Study NCT06120452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rael Miracle Clear Complete Acne Serum
Description: This acne serum contains the following ingredients:~1.5% Salicylic acid. 2% Niacinamide. 0.5% Zinc Pyrrolidone Carboxylic Acid (PCA). Hyaluronic Acid.
Study NCT04953481 — intervention group
Intervention type: OTHER
Intervention: survey
Description: The general information, home care status and functional status of ALS patients and family caregivers were collected.
Study NCT05813249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozempic Injectable Product
Description: Subcutaneous Semaglutide
Study NCT05813249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocopherol and/or Actos
Description: Vitamin E and/or Pioglitazone
Study NCT05993832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: input cue
Description: The object is labelled with 1) gaze only; 2) novel label only; or 3) conflicting gaze and novel label
Study NCT05313503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: We propose a type of KD named MAD (Modified Atkins Diet) characterized by the following percentages of macronutrients: 65% fats, 27% proteins and 8% carbohydrates.
Study NCT05762510 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GMCN-508B (LentiRed)
Description: LentiRed Drug Product is administered by intravenous infusion following myeloablative conditioning with busulfan.
Study NCT04711278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mask-wearing hypnosis
Description: Virtual mask will be worn by patients before and during surgery of Hallux valgus to realize hypnosis.~Virtual mask with 2 types of voice: female voice and male voice. Several types of image or music to choice by patient.
Study NCT04711278 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Without hypnosis
Description: No hypnosis during surgery of Hallux valgus.
Study NCT05532046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2413555 Dose 1
Description: BAY2413555 Dose 1
Study NCT05532046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2413555 Dose 2
Description: BAY2413555 Dose 2
Study NCT05532046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BAY2413555
Description: Placebo to BAY2413555
Study NCT05785221 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General lifestyle and nutritional education
Description: Participants will receive general dietary advice, behavior guidance and nutritional and lifestyle education based on dietary guidelines.
Study NCT05785221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized nutritional and lifestyle weight reduction intervention
Description: Participants will receive personalized dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians. APP-connected wearable devices will be utilized to monitor their dietary intakes, physical activities and sleep conditions and APP-connected scale will be used to monitor their weight changes during interventions.
Study NCT06325176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: During the 1st visit of the patients, they will be assessed for pain and episiotomy wound. The cryotherapy group will include 12 postnatal women. This group will use a bag of ice pack applied to the perineal region. The ice pack will be sealed in plastic bag and wrapped with one layer of a thin cotton tissue so that the skin of the participant would not be in direct contact with ice, which could cause discomfort. During the intervention, the women will be asked to remove their underpants and hygienic pads and remain in the dorsal recumbent position during cryotherapy that lasted 20 minutes. This procedure will be done twice a day for seven consecutive days
Study NCT06325176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrared light therapy
Description: Infrared group will include 12 postnatal women they will encourage to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for twenty minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researcher will demonstrate for each woman how to use infrared lamp, and it will be followed by re demonstrations and discussions. These procedures will carry out in the morning and evening for seven consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study
Study NCT06558201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.
Study NCT06539494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 40 MG
Description: Proton pump inhibitor twice a day for 4 weeks
Study NCT00648479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Guiding Star
Study NCT00648479 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fluoroscopy (OEC 9800 - General Electric)
Study NCT06210256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unidirectional valve apparatus
Description: In the unidirectional valve group, we attached the unidirectional valve device to the lumen's distal port when one-lung ventilation initiated.
Study NCT06210256 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: occluding the non-ventilated endobronchial lumen
Description: In the closed operative lumen group, we closed the lumen's distal port of non-ventilated lung when one-lung ventilation initiated.
Study NCT04336202 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: External beam radiotherapy + Endorectal brachytherapy
Description: In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
Study NCT05157646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness tracker
Description: Participants will be asked to wear a Fitbit fitness tracker and report their fitness activity to the study team
Study NCT04782323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aQII-1
Description: Biological/Vaccine: Investigational aQII-1 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study NCT04782323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aQII-3 Investigational
Description: Biological/Vaccine: Investigational aQII-3 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study NCT04782323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aQII-6 Investigational
Description: Biological/Vaccine: Investigational aQII-6 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study NCT04782323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aQII-7 Investigational
Description: Biological/Vaccine: Investigational aQII-7 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study NCT04782323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aQII-9 Investigational
Description: Biological/Vaccine: Investigational aQII-9 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study NCT04782323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aQII-10 Investigational
Description: Biological/Vaccine: Investigational aQII-10 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study NCT04782323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aQII-11 Investigational
Description: Biological/Vaccine: Investigational aQII-11 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study NCT04782323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Licensed QII Active Comparator
Description: Biological/Vaccine: Licensed QII Licensed Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study NCT05511987 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Madela THOPAZ Digital Device
Description: Digital drainage systems use electronic sensors to measure changes in pressure and thus may allow for quantification of the degree of air leak continuously and provide a graphical representation of the trend over time. Data on intrapleural pressure are also provided by some units. Together, these data may lead to expedited chest tube removal and hospital discharge with obvious financial implications.
Study NCT05511987 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atrium Analog Device
Description: Analog drainage systems contain a sequentially numbered series of columns in the water seal chamber. The degree of air leak is assessed by observing the highest numbered column in which bubbling occurs. This provides a qualitative assessment at a specific point in time. This assessment, however, is subject to interobserver variability and does not account for variation over time.
Study NCT05558059 — intervention group
Intervention type: DEVICE
Intervention: Handheld Optical Coherence Tomography with OCT Angiography
Description: OCT systems are in vivo optical imaging technology that allows non-contact imaging of early-stage ocular pathology. They create real-time, non-invasive images of ocular microstructure and have become standard-of-care instruments in ophthalmic imaging in clinics and operating rooms. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are analyzed for depth-resolved information and can also be stacked to create a volume and the stack may be summed up to create a retinal image.~OCT angiography (OCTA) is an extension of the OCT systems, by taking images at the same location over time to extract retinal vascular flow information. It has been utilized to assess the ocular blood flow in many adult and pediatric patients.
Study NCT06539091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
Study NCT06539091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are also required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
Study NCT06538103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eye soft surgery
Description: Early lower eyelid surgery will be performed in accordance with the protocol previously described by Di Stadio, with medial or lateral eyelid lifting surgery as indicated. The indication for eye surgery are in case of ectropion (exposure of the conjunctiva due to a reduction in tension of the anterior compartment of the eye muscle) and lagophthalmos (incomplete /abnormal closure of the eye with eyelid in closed position) a lateral lower eyelid lifting surgery is performed. otherwise, in presence of epiphora (the eversion of the lachrymal point) and lagophthalmos medial lower eyelid lifting surgery is done.
Study NCT06538103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Rehabilitation
Description: Kabat therapy and neuromuscular reeducation (NMR) at home Kabat therapy involved thrice-weekly 35-minute sessions.
Study NCT06538103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Rehabilitation
Description: Kabat therapy and neuromuscular reeducation (NMR) at home Kabat therapy involved thrice-weekly 35-minute sessions.
Study NCT05101356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antineoplastic Vaccine
Description: Given LabVax 3(22)-23 ID
Study NCT05101356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study NCT05101356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV per standard of care
Study NCT04767217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artemether-lumefantrine (ALN)
Description: Assessing the efficacy on current 1st line antimalarial, and an alternative 1st line or 2nd line medicine
Study NCT04767217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin-piperaquine (DHA-PPQ)
Description: dihydroartemisinin-piperaquine (DHA-PPQ)
Study NCT06224478 — intervention group
Intervention type: OTHER
Intervention: Measurement of palatal mucosa thickness on CBCT scans
Description: Measurement of palatal mucosa thickness on CBCT scans in hypodovergent, normodivergent and hyperdivergent patients
Study NCT06572670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercise before coronary angiography
Description: Patients in the intervention group will undergo progressive relaxation before undergoing angiography.
Study NCT05599594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: 6 drops of aromatic oils used by the researcher will be dripped by the aromatic oils to take the fragrance by inhalation for 30 minutes.
Study NCT04701021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TENDU
Description: The vaccine is administrated by subcutaneous injections, one injection per drug substance (four separate injections) consecutively.